Amedisys Inc. (AMED) has been moving in a narrow range since the open Monday, but has climbed higher in the last 20 minutes. The stock is now up 1.94 at $51.78.
December 29, 2009
Zhongpin Inc. Has Broken Out Of Today’s Range
Zhongpin Inc. (HOGS) has been moving in a narrow range since the open Monday, but has broken out higher in the last few minutes on increased volume. The stock is now up 0.54 at $15.14.
STEC Inc. Has Re-Crossed Its 50-Day Moving Average
STEC Inc. (STEC) has been climbing for the majority of early trade Monday morning. The stock is now up 1.13 at $16.83.
Vical Inc. Has Re-Crossed Its Moving Averages
Vical Inc. (VICL) announced Monday morning that an independent Safety Monitoring Board for its Phase 3 AIMM trial of Allovectin-7, in patients with metastatic melanoma, completed the trial’s third scheduled safety analysis and recommended that the trial continue per the protocol.
American International Group Is Rising In Early Trade
American International Group (AIG) has been climbing since the open of trade Monday. Shares are currently higher by 2.37 at $32.49.
American Science & Engineering Has Risen Above A Trading Range
American Science & Engineering (ASEI) gapped open higher Monday and is now up 4.53 at $76.23.
OSI Systems Inc. Has Gapped Up To A New High For The Year
OSI Systems Inc. (OSIS) gapped open higher Monday morning and is currently up 1.83 at $23.85.
RINO International Corp. Has Risen Above Today’s Range
RINO International Corp. (RINO) gapped up at the open Wednesday, but has since traded in a narrow range. Shares have broken out higher in the last few minutes on increased volume and are now up 1.53 at $29.10.
FSI International Inc. Is Rising On Q1 Results
FSI International Inc. (FSII) reported break-even first quarter earnings after the close Tuesday, compared to the loss of $0.17 per share posted last year.
PSivida Corp. Is Rising On Study Results
pSivida Corp. (PSDV) reported results from the Phase III FAME study of Iluvien Wednesday morning, for the treatment of Diabetic Macular Edema. The primary efficacy endpoint was met with statistical significance for both doses of Iluvien.